MariTime HF
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Obesity and Heart Failure
- Stage
- inclusie
- Medicine
- Meridebart Cafraglutide
- Population
- Hartfalen
- Phase
- III
- First Patient In
- 14 October 2025
- Last Patient In
- 28 October 2026
- Last Patient Last Visit
- 29 September 2030
Inclusion period, 333 days remaining
National Lead
dr. P van der Meer
Cardioloog
Study Director
dr. C.A. da Fonseca
Cardioloog
Office Contact
